LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the…
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by…
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a…
Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in…
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4…
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)…
RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327…
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and…